• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Sunshine Biopharma (NQ: SBFM )

    2.610 -0.080 (-2.97%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 11, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Sunshine Biopharma

    Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54%
    Via ACCESSWIRE
    Sunshine Biopharma Launches Two New Generic Prescription Drugs
    Via ACCESSWIRE
    New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
    EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:NVAX),(NASDAQ:RGNX),(NASDAQ:BNTX),(NYSE:ABBV) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Exposures COVID-19
    Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry
    Via ACCESSWIRE
    Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023
    Via ACCESSWIRE
    Insider Buying: Sunshine Biopharma Inc. (NASDAQ: SBFM) Chief Financial Officer Purchases Shares
    To learn more about Sunshine Biopharma, download the latest research report here 
    Via TheNewswire.com
    Exposures COVID-19
    NASDAQ: SBFM 👥 Enters Into A Collaboration Agreement For Its K1.1 Anticancer mRNA Project! 🔬
    Christine Petraglia - TraDigital IR 
    Via TheNewswire.com
    New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
    From FN Media Group LLC
    Via GlobeNewswire
    Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
    EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Exposures COVID-19
    Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
    From FN Media Group LLC
    Via GlobeNewswire
    SUNSHINE BIOPHARMA ANNOUNCES PUBLICATION OF SIGNIFICANT CORONAVIRUS RESEARCH RESULTS IN THE JOURNAL OF MEDICINAL CHEMISTRY
    Current Test Positivity Rate for Coronavirus Infection in the U.S. is 18% Development of a novel antiviral compound, XR8-23 (Compound 10), targeting SARS-CoV-2 papain-like protease (PLpro) with both... 
    Via FinancialNewsMedia
    Exposures COVID-19
    Sunshine Biopharma Has Launched Nine New Generic Prescription Drugs in 2024: Now Marketing Sixty-One Generic Drugs in Canada
    Via ACCESSWIRE
    Sunshine Biopharma Reports 2024 Second Quarter Results: Second QTR Revenues up 67%, YTD Revenues up 61%
    Via ACCESSWIRE
    Sunshine Biopharma Announces Reverse Stock Split
    Via ACCESSWIRE
    Sunshine Biopharma Reports 2024 First Quarter Results: Revenues Up 54%
    Via ACCESSWIRE
    Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)
    Via ACCESSWIRE
    Sunshine Biopharma Announces Reverse Stock Split
    Via ACCESSWIRE
    BioMedNewsBreaks — Sunshine Biopharma Inc. (NASDAQ: SBFM) Closes on $10M Public Offering
    Via Investor Brand Network
    Exposures COVID-19
    Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering
    Via ACCESSWIRE
    Sunshine Biopharma Reports 2023 Third Quarter Results: Revenues up Significantly Over Last Year Due to a Key Acquisition
    Via ACCESSWIRE
    Aegis Capital Corp. Acted as Exclusive Placement Agent on a $5.0 Million Private Placement Priced At-the-Market for Sunshine Biopharma, Inc. (NASDAQ:SBFM)
    Via ACCESSWIRE
    Coronavirus Vaccine Market To Surpass $95 Billion By 2028
    EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NASDAQ:NVAX),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Exposures COVID-19
    SUNSHINE BIOPHARMA SIGNS EXCLUSIVE WORLDWIDE LICENSE WITH UNIVERSITY OF ARIZONA FOR PLpro-BASED COVID-19 TREATMENT
    Montreal – February 28, 2023 – Sunshine Biopharma Inc. (NASDAQ: SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and... 
    Via FinancialNewsMedia
    Exposures COVID-19 Product Safety
    Chinese Lockdown Effects Ripple Marketwide; A Solution Urgently Needed
    Read the latest report on Sunshine Biopharma here. 
    Via TheNewswire.com
    Exposures COVID-19
    One in Five Americans Who Have Been Infected With the Virus Said to Have Long COVID
    Palm Beach, FL – November 17, 2022 – FinancialNewsMedia.com News Commentary – Since the beginning of the pandemic, the critical effort of researchers is to understand how coronavirus damages the body.... 
    Via FinancialNewsMedia
    Exposures COVID-19
    Aegis Capital Corp. acted as Exclusive Placement Agent on a $19.5 Million Private Placement Priced At-the-Market for Sunshine Biopharma Inc. (NASDAQ: SBFM)
    Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
    From Aegis Capital Corp.
    Via AccessWire
    Topics Intellectual Property
    Exposures COVID-19 Intellectual Property
    Advanced Immunological and Clinical Trials for Treating Ovarian Cancer Accelerating
    Palm Beach, FL – April 25, 2022 – FinancialNewsMedia.com News Commentary – The formation of mutational cells or tissues in female reproductive organs called ovaries leads to ovarian cancer. Cancer... 
    Via FinancialNewsMedia
    Topics Intellectual Property
    Exposures Intellectual Property
    Aegis Capital Corp. acted as Exclusive Placement Agent on an $8 Million Private Placement for Sunshine Biopharma Inc. (NASDAQ: SBFM)
    NEW YORK, NY / ACCESSWIRE / March 15, 2022 / Aegis Capital Corp. acted as Exclusive Placement Agent on an $8 Million Private Placement for Sunshine Biopharma Inc. (NASDAQ:SBFM) About Sunshine... 
    From Aegis Capital Corp.
    Via AccessWire
    Exposures COVID-19
    Aegis Capital Corp. acted as Sole Bookrunner on an Uplist of an $8 Million Underwritten Public Offering for Sunshine Biopharma Inc. (NASDAQ: SBFM; SBFMW)
    NEW YORK, NY / ACCESSWIRE / February 17, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on an Uplist of an $8 Million Underwritten Public Offering for Sunshine Biopharma Inc. (NASDAQ:SBFM; SBFMW)... 
    From Aegis Capital Corp.
    Via AccessWire
    Exposures COVID-19
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.